Today: 21 May 2026
Visa stock slips toward $350 as proxy-season filings hit ahead of annual meeting
10 January 2026
1 min read

Visa stock slips toward $350 as proxy-season filings hit ahead of annual meeting

New York, Jan 10, 2026, 05:05 EST — Market closed

  • Visa ended Friday down 0.7% at $349.77, after touching a session low of $349.16.
  • A shareholder group urged investors to back a proposal seeking more disclosure on risks tied to deepfake content and payment activity.

Visa Inc shares closed down 0.7% on Friday at $349.77, leaving the stock about 7% below its 52-week high, after a shareholder filing pushed a fresh proposal into focus ahead of the company’s annual meeting.

The filing matters because it lands in the narrow window when big funds start sizing up proxy ballots and headline risk can whipsaw a steady, “defensive growth” name like Visa. It also comes after two straight down sessions for the stock, at a time when investors have been quick to fade anything that looks like distraction.

Visa fell even as the broader market rose on Friday, underperforming a rally that lifted the S&P 500 by 0.65%.

In its proxy materials, Visa has laid out the usual director elections and executive-pay vote, alongside shareholder proposals that can draw attention even when they rarely pass.

Beyond the proxy noise, traders are still treating the next results as the real test. In October, Visa forecast low double-digit net revenue growth for fiscal 2026; CFO Chris Suh said on the post-earnings call, “We saw broad-based strength, including improvements in retail services and goods, travel and fuel.” Reuters

Some investors have also been watching Visa’s push into tokenization — swapping card numbers for a digital token — which can cut fraud and smooth checkout, and has been pitched as more than just a security upgrade.

But cross-border growth, a key driver of fees for the payments networks, is what makes or breaks the quarter, and softer travel demand can show up fast in those numbers. Visa’s last reported quarter showed cross-border volume up 12%, and the company flagged continued strength in consumer spending, but investors remain alert to any cooling at the margin.

The next marker is Visa’s annual meeting on Jan. 27, followed by its next earnings report, which Nasdaq estimates for Jan. 29.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Previous Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy
Next Story

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

Go toTop